(Q39527047)

English

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.

scientific article published on September 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

Michele Caraglia

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Francesca Bruzzese

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Alessandra Leone

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Carmine Carbone

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Elena Di Gennaro

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Alfredo Budillon

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Monia Rocco

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 September 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Journal of Cellular Physiology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

226

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

2378-2390

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21660961%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Frequent overexpression of multiple ErbB receptors by head and neck squamous cell carcinoma contrasts with rare antibody immunity in patients.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Molecular therapy in head and neck oncology

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

HDACi--targets beyond chromatin.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

The met receptor degradation pathway: requirement for Lys48-linked polyubiquitin independent of proteasome activity

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Epithelial-mesenchymal transition and the invasive potential of tumors.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Histone deacetylases and cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Differential regulation of EGF receptor internalization and degradation by multiubiquitination within the kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Epidermal growth factor receptor biology in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Proteomic identification of ubiquitinated proteins from human cells expressing His-tagged ubiquitin

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Discovery and development of SAHA as an anticancer agent

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Low incidence of ras oncogene activation in human squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

The ERBB3 receptor in cancer and cancer gene therapy

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

New colorimetric cytotoxicity assay for anticancer-drug screening

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

HDAC expression and clinical prognosis in human malignancies

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

The morphological and molecular features of the epithelial-to-mesenchymal transition

1 reference

https://api.crossref.org/works/10.1002%2FJCP.22574

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39527047&oldid=1642315341"